$MED

Insider Stock Purchases: August 28, 2026

On August 28, 2026, 183 insider stock purchases were reported. Notable transactions include Klarna Group's CEO buying 692,506 shares for $9.95M, Medifast's Kiai Parsa purchasing 41,975 shares for $514,747, and Regenxbio's Ciongoli buying 53,407 shares for $499,675. Hawkins' Lange and FTC Solar's Sadasivam also made significant purchases.

Original reporting
Published Aug 28, 2026, 6:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 1:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Insider Stock Purchases: August 28, 2026 — source image
Decision brief

The 30-second read

$MEDNeutralLow
01

Why it matters

These filings provide fresh, primary‑source data but involve modest transaction sizes, limiting immediate trading relevance.

02

Market read

Insider buying signals modest confidence but transaction sizes are small; overall market impact is low.

03

What to watch

Potential upcoming corporate actions or clinical trial news not disclosed yet.

Relevance 4/10Novelty 3/10Timing: today

Background

The article aggregates recent Form 4 insider purchase filings reported by QuiverQuant for August 28 2026.

Company-level read

Ticker impact

$MEDNeutralMedium confidence
Context

Medifast Inc. insider Kiai Parsa purchased 41,975 shares for $514,747 on 08/26.

Expected impact

Potential slight price uptick if market perceives confidence.

Evidence & confidence

Purchase size is modest relative to market cap; limited immediate impact.

$RGNXNeutralMedium confidence
Context

Regenxbio Inc. insider Gregory Austin bought 53,407 shares for $499,675 on 08/27.

Expected impact

Minimal short‑term effect; may support slight bullish bias.

Evidence & confidence

Buy amount is under $1M, typical for biotech insiders, unlikely to move price materially.

$HWKNNeutralLow confidence
Context

Hawkins Inc. insider Douglas Lange bought 910 shares for $108,065 on 08/25.

Expected impact

Negligible impact.

Evidence & confidence

Purchase is tiny relative to float; market likely ignores.

$FTCINeutralLow confidence
Context

FTC Solar, Inc. insider Shaker Sadasivam purchased 33,290 shares for $72,905 on 08/26.

Expected impact

Little to no price movement expected.

Evidence & confidence

Purchase amount is modest; market reaction expected to be muted.

Market effects

Limited; insider activity in health and renewable sectors may be noted by sector traders.

None significant.

Low.

Counterpoint

Insider purchases are routine and may not indicate real upside; focus on fundamentals.

Key entities

  • Medifast Inc.

    Health and nutrition company; insider purchases reported.

  • Regenxbio Inc.

    Biotech firm; insider purchase reported.

  • Hawkins Inc.

    Water treatment company; insider purchase reported.

  • FTC Solar, Inc.

    Solar energy firm; insider purchase reported.

Related articles

$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

HighAI 8/10

Why Hawkins Stock Crushed the Market on Tuesday

Hawkins reported Q2 2027 revenue of $314M, up 12% YoY, and EPS of $1.34, up 23% YoY, beating analyst estimates. All three segments grew, with water treatment up 16%. The stock rose 14% on Tuesday, outperforming the S&P 500. The company reduced debt and repurchased stock.

$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

$HWKNHighAI 8/10

Hawkins (NASDAQ:HWKN) Shares Rise 8% After Q2 Earnings Exceed Estimates and Revenue Reaches $313.8 Million

Hawkins (HWKN) shares rose 8% after Q2 earnings beat estimates, with revenue up 12% to $313.8M, net income up 23% to $27.8M, and adjusted EBITDA up 16% to $59.1M. The company declared a $0.20 dividend, repurchased $12M in shares, and completed two acquisitions. All three operating segments saw revenue growth, led by a 16% increase in Water Treatment.

$MEDMed

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.